glp-1 drugs shortage Diabetes Patients Also Struggle to Access Agonists fda glp 1 compounding The

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

For drugs with a narrow therapeutic index, other factors need to be monitored closely, including plasma drug levels, patients clinical outcomes, and laboratory markers

The GLP-1 Receptor Agonist Market worth USD 2.9 billion in 2026 is growing at a CAGR of 11.7% to reach USD 7.8 billion by 2036

Access up-to-date information on glucoregulatory hormones and GLP-1/GIP receptor agonists with clinical guidance at Healio.

Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels